Biotechnology Stocks
| # | 이전 7일 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 2012 |  NVAX Novavax, Inc. - Common Stock | 11.01 USD | -1.87% | +2.32% | +14.21% | +27.87% | 1.82 B USD | ||
| 2019 |  URGN UroGen Pharma Ltd. - Ordinary Shares | 36.98 USD | -9.14% | -9.65% | -15.61% | +94.63% | 1.81 B USD | ||
| 2022 |  BHVN Biohaven Ltd. Common Shares | 11.94 USD | +0.34% | -10.70% | -17.66% | -29.52% | 1.80 B USD | ||
| 2027 |  ZYME Zymeworks Inc. - Common Stock | 25.26 USD | -4.79% | -2.77% | -9.17% | +42.39% | 1.79 B USD | ||
| 2031 |  MESO Mesoblast Limited - American Depositary Shares | 13.75 USD | -1.36% | -4.11% | -12.97% | -27.97% | 1.78 B USD | ||
| 2039 |  NTLA Intellia Therapeutics, Inc. - Common Stock | 12.60 USD | +7.60% | +1.45% | +0.80% | -8.16% | 1.77 B USD | ||
| 2046 |  NUVB Nuvation Bio Inc. Class A Common Stock | 4.98 USD | +2.26% | -12.01% | -22.07% | +31.40% | 1.75 B USD | ||
| 2053 |  SEPN Septerna, Inc. - Common Stock | 36.90 USD | +2.50% | -4.99% | -0.67% | +67.65% | 1.72 B USD | ||
| 2060 |  ZBIO Zenas BioPharma, Inc. - Common Stock | 26.24 USD | -6.88% | -7.83% | -20.53% | -0.83% | 1.71 B USD | ||
| 2087 |  OCUL Ocular Therapeutix, Inc. - Common Stock | 7.51 USD | +3.87% | +1.21% | -33.19% | -34.70% | 1.65 B USD | ||
| 2121 |  QURE uniQure N.V. - Ordinary Shares | 22.54 USD | -2.59% | -4.97% | -50.66% | -64.64% | 1.56 B USD | ||
| 2126 |  STOK Stoke Therapeutics, Inc. - Common Stock | 23.95 USD | -1.40% | -9.04% | -19.14% | -22.62% | 1.55 B USD | ||
| 2130 |  ABSI Absci Corporation - Common Stock | 8.94 USD | -3.04% | -19.75% | +6.81% | +122.39% | 1.53 B USD | ||
| 2143 |  SNDX Syndax Pharmaceuticals, Inc. - Common Stock | 16.90 USD | -0.76% | -8.45% | -14.08% | +3.81% | 1.51 B USD | ||
| 2144 |  INVA Innoviva, Inc. - Common Stock | 20.87 USD | -0.90% | +1.31% | -1.37% | +17.12% | 1.51 B USD | ||
| 2145 |  RARE Ultragenyx Pharmaceutical Inc. - Common Stock | 15.29 USD | +2.69% | +2.62% | +7.60% | -51.93% | 1.51 B USD | ||
| 2152 |  IMCR Immunocore Holdings plc - American Depositary Shares | 29.09 USD | -1.09% | -5.49% | -17.26% | -13.11% | 1.50 B USD | ||
| 2165 |  TSHA Taysha Gene Therapies, Inc. - Common Stock | 4.43 USD | 0.00% | -7.71% | -15.46% | -12.97% | 1.44 B USD | ||
| 2192 |  NKTR Nektar Therapeutics - Common Stock | 40.80 USD | +1.34% | -11.78% | -45.67% | -44.32% | 1.39 B USD | ||
| 2198 |  OMER Omeros Corporation - Common Stock | 19.12 USD | +1.97% | +2.80% | 0.00% | +316.56% | 1.38 B USD |
뉴스 Biotechnology Stocks
RBC 캐피털, 리듬 파마슈티컬스에 대한 ‘시장수익률 상회’ 의견 유지···목표주가 159달러로 상향
RBC 캐피털, 엑셀리시스 투자의견 ‘시장수익률’ 유지·목표주가 45달러로 하향
ADC 테라퓨틱스, 주당 1.42달러에 1,290만 주 및 주당 1.32달러에 4,810만 주 매입 워런트 제공하는 8,660만 달러 규모 파이프 파이낸싱 발표; 대출 및 로열티 수정 확보
뉴트리밴드, AVERSA 남용 억제 경피 기술 보호 강화 위해 미국 특허 출원
바이오라인RX, GLIX1 관련 초록 2편이 11월 12~15일 신경종양학회 연례회의에서 발표될 예정이라고 발표
아트리움 테라퓨틱스, 5,170,384주 및 사전 자금 조달 워런트 최대 1,134,930주 매입을 위한 약 7.93달러/주당 5천만 달러 규모의 사모 발표
러시아, 시베리아에서 두 번째 발병 사례 보도 부인 - 블룸버그
Gainers Biotechnology Stocks
 GRDX GridAI Technologies Corp. - Common Stock | 4.80 | +16.50% |
 CLGN CollPlant Biotechnologies Ltd. - Ordinary Shares | 3.97 | +14.74% |
 IPSC Century Therapeutics, Inc. - Common Stock | 1.46 | +14.06% |
 ADCT ADC Therapeutics SA Common Shares | 1.59 | +11.97% |
 CDTTW CDT Equity Inc. - Warrant | 0.0117 | +11.43% |
 SRZN Surrozen, Inc. - Common Stock | 27.97 | +11.26% |
 ANL Adlai Nortye Ltd - American Depositary Shares | 15.51 | +10.39% |
 QNCX Quince Therapeutics, Inc. - Common Stock | 29.36 | +9.88% |
Losers Biotechnology Stocks
 SABSW SAB Biotherapeutics, Inc. - Warrant | 0.0088 | -27.87% |
 YDESW YD Bio Limited - Warrants | 0.5000 | -23.08% |
 CRBU Caribou Biosciences, Inc. - Common Stock | 0.48 | -22.58% |
 TCRX TScan Therapeutics, Inc. - Common Stock | 0.23 | -17.86% |
 KALA KALA BIO, Inc. - Common Stock | 0.30 | -16.67% |
 BRTX BioRestorative Therapies, Inc. - Common Stock | 1.89 | -15.62% |
 MLEC Moolec Science SA - Ordinary Shares | 4.19 | -12.89% |
 LPCN Lipocine Inc. - Common Stock | 1.93 | -12.27% |